Dominican Republic Specific Pollen Allergies Market – Industry Trends and Forecast to 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO-

4.4 INVENTION PATENT-

4.5 COUNTRY LEVEL ANALYSIS

5 REGULATIONS

5.1 DOMINICAN REPUBLIC

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER

6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER

6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION

6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING

6.2 RESTRAINTS

6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS

6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS

6.3 OPPORTUNITIES

6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION

6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS

6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING

6.4 CHALLENGES

6.4.1 INCREASE IN ABUSE POTENTIAL

6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW

7 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE

7.1 OVERVIEW

7.2 ANTIHISTAMINE

7.2.1 ANTIHISTAMINE, BY DRUG TYPE

7.2.2 LEVOCETIRIZINE

7.2.3 CETIRIZINE

7.2.4 LORATIDINE

7.2.5 DIPHENHYDRAMINE

7.2.6 CHLORPHENIRAMINE

7.2.7 FEXOFENADINE

7.3 CORTICOSTEROIDS

7.3.1 FLUTICASONE PROPIONATE

7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID

7.3.3 CROMOLYN SODIUM

7.3.4 OTHERS

7.4 DECONGESTANTS

7.4.1 DECONGESTANTS, BY DRUG TYPE

7.4.2 PSEUDOEPHEDRINE

7.4.3 PHENYLEPHRINE

7.4.4 OXYMETAZOLINE

7.4.5 OTHERS

7.5 ANTICHOLINERGICS

7.5.1 ANTICHOLINERGICS, BY DRUG TYPE

7.5.2 IPRATROPIUM BROMIDE

7.5.3 OTHERS

7.6 OTHERS

8 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 INSTRUMENTS

8.2.1 IMMUNO ASSAY ANALYZER

8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER

8.3 RADIO IMMUNO ASSAY (RIA)

8.4 COUNTING IMMUNO ASSAY (CIA)

8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA)

8.6 FLUOROIMMNOASSAY (FIA)

8.7 CHEMILUMINESCENCE ASSAY

8.7.1 LUMINOMETERS

8.8 REAGENTS AND KITS

8.9 OTHERS

9 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST

9.1 OVERVIEW

9.2 IN VIVO TEST

9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST

9.2.2 SKIN PRICK

9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST

9.2.2.2 GREER PRICK

9.2.3 THE STELLAR POINT

9.2.4 PHAZET

9.2.5 BIFURCATED SMALLPOX VACCINATION TEST

9.2.6 23G INTRAVENOUS NEEDLE

9.2.7 OTHERS

9.2.8 PATCH TEST

9.2.9 INTRADERMAL TEST

9.3 IN VITRO TEST

9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST

9.3.2 SERUM SPECIFIC IGE ASSAY

9.3.3 TOTAL IGE ASSAY

9.3.4 BASOPHIL ACTIVATION TEST

10 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 DIAGNOSTICS LABORATORIES

10.4 ACADEMIC AND RESEARCH INSTITUTES

10.5 OTHERS

11 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.3.1 RETAIL SALES, BY TYPE

11.3.2 HOSPITAL PHARMACY

11.3.3 RETAIL PHARMACY

11.3.4 ONLINE PHARMACY

12 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 GLAXOSMITHKLINE PLC

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENTS

14.2 JOHNSON & JOHNSON SERVICES, INC

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENTS

14.3 PERRIGO COMPANY PLC

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENTS

14.4 SIEMENS HEALTHCARE GMBH

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 PRODUCT PORTFOLIO

14.4.4 RECENT DEVELOPMENTS

14.5 THERMO FISHER SCIENTIFIC INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.6 BAYER AG

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 ALCON INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BIOMÉRIEUX, SA.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 CINFA LABORATORIES

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 CIRCASSIA

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 LINCOLN DIAGNOSTICS, INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 MINARIS MEDICAL AMERICA, INC.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 PRESTIGE CONSUMER HEALTHCARE INC.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

14.15 QUEST DIAGNOSTICS INCORPORATED

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENT

14.16 SANOFI

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS